Glioma　features　high　fatality　rate　and　short　survival　time　of　patients　due　to　its　fast　growth　speed　and　high　invasiveness,　hence　timely　treatment　of　early-stage　glioma　is　extremely　important.　However,　the　blood　brain　barrier　(BBB)　severely　prevents　therapeutic　agents　from　entering　the　brain;　meanwhile,　the　non-targeted　distribution　of　agents　always　causes　side　effects　to　vulnerable　cerebral　tissues.　Therefore,　delivery　systems　that　possess　both　BBB　penetrability　and　precise　glioma　targeting　ability　are　keenly　desired.　We　herein　proposed　a　hybrid　cell　membrane　(HM)　camouflage　strategy　to　construct　therapeutic　nanocomposites,　in　which　HM　consisting　of　brain　metastatic　breast　cancer　cell　membrane　and　glioma　cell　membrane　was　prepared　with　a　simple　membrane　fusion　pathway.　By　coating　HM　onto　drug-loaded　nanoparticles,　the　as-obtained　biomimetic　therapeutic　agent　(termed　HMGINPs)　inherited　satisfying　BBB　penetrability　and　homologous　glioma　targeting　ability　simultaneously　from　the　two　source　cells.　HMGINPs　exhibited　good　biocompatibility　and　superior　therapeutic　efficacy　towards　early-stage　glioma.